HLA-Compass für sichere Immuntherapien
Winner
Excellence in Business to Business
Medical Technologies
Details
Alithea Bio: HLA-Compass – Mapping Precision Medicine Alithea Biotechnology transforms oncology into a predictive science. Our cloud-based platform, HLA-Compass, is the catalyst for next-generation immunotherapies. By providing direct access to the functional immunopeptidome, we bridge the gap where conventional methods fail. Featuring 1.56M identified peptides and 10,000 cancer epitopes, we offer the world’s most validated human database. Our AI predicts HLA binding with surgical precision, minimizing off-target risks and accelerating the journey from lab to patient. We make safe, personalized cancer care accessible for every genotype.
The Jury‘s Statement
The development of safe immunotherapies requires precise and comprehensive data in order to be targeted and effective. HLA-Compass offers an innovative cloud-based platform that enables accelerated discovery and validation of safe immunotherapies by providing access to an extensive, high-quality database of peptides and cancer-specific epitopes. The broad coverage of different HLA types, combined with an AI-supported binding prediction tool, creates an efficient and user-oriented solution that significantly advances research and development in this field. HLA-Compass thus combines technological innovation with practical application and provides new impetus for the future of immunotherapy.
